Teva to Host Conference Call to Discuss First Quarter 2021 Financial Results at 8 a.m. ET on April 28, 2021
06 April 2021 - 11:42PM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
announced today that it will issue a press release on its financial
results for the first quarter on Wednesday, April 28, 2021 at 7:00
a.m. ET. Following the release, Teva will conduct a conference call
and live webcast on the same day, at 8:00 a.m. ET.
In order to participate, please dial the following numbers (at
least 10 minutes before the scheduled start time): United States
1-866-966-1396; Israel 1-809-203-624 or International +44 (0) 2071
928000; passcode: 8347148.
A live webcast of the call will be available on Teva's website
at: http://ir.tevapharm.com/. Please log in at least 10 minutes
prior to the conference call in order to download the applicable
audio software.
Following the conclusion of the call, a replay of the webcast
will be available within 24 hours on the Company's website or by
calling United States 1-866-331-1332; International +44 (0) 3333
009785; passcode: 8347148.
About Teva Teva Pharmaceutical Industries Ltd. (NYSE and
TASE: TEVA) has been developing and producing medicines to improve
people’s lives for more than a century. We are a global leader in
generic and specialty medicines with a portfolio consisting of over
3,500 products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the conference call may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, which are based on
management’s current beliefs and expectations and are subject to
substantial risks and uncertainties, both known and unknown, that
could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our
ability to successfully compete in the marketplace; our substantial
indebtedness; our business and operations in general; compliance,
regulatory and litigation matters; other financial and economic
risks; and other factors discussed in our Annual Report on Form
10-K for the year ended December 31, 2020, including in the
sections captioned “Risk Factors.” Forward-looking statements speak
only as of the date on which they are made, and we assume no
obligation to update or revise any forward-looking statements or
other information contained herein, whether as a result of new
information, future events or otherwise. You are cautioned not to
put undue reliance on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210406005705/en/
IR Contacts United States Kevin C. Mannix (215) 591-8912
Israel Yael Ashman +972 (3) 914 8262 PR Contacts
United States Kelley Dougherty (973) 832-2810 Israel
Yonatan Beker +972 (54) 888 5898
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Apr 2023 to Apr 2024